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BACKGROUND: Contemporary screening for prostate cancer frequently identifies small volume, low-grade lesions. Some clinicians have
advocated focal prostatic ablation as an alternative to more aggressive interventions to manage these lesions. To identify which
patients might benefit from focal ablative techniques, we analysed the surgical specimens of a large sample of population-detected
men undergoing radical prostatectomy as part of a randomised clinical trial.
METHODS: Surgical specimens from 525 men who underwent prostatectomy within the ProtecT study were analysed to determine
tumour volume, location and grade. These findings were compared with information available in the biopsy specimen to examine
whether focal therapy could be provided appropriately.
RESULTS: Solitary cancers were found in prostatectomy specimens from 19% (100 out of 525) of men. In addition, 73 out of 425 (17%)
men had multiple cancers with a solitary significant tumour focus. Thus, 173 out of 525 (33%) men had tumours potentially suitable
for focal therapy. The majority of these were small, well-differentiated lesions that appeared to be pathologically insignificant
(38–66%). Criteria used to select patients for focal prostatic ablation underestimated the cancer’s significance in 26% (34 out of 130)
of men and resulted in overtreatment in more than half. Only 18% (24 out of 130) of men presumed eligible for focal therapy,
actually had significant solitary lesions.
CONCLUSION: Focal therapy appears inappropriate for the majority of men presenting with prostate-specific antigen-detected
localised prostate cancer. Unifocal prostate cancers suitable for focal ablation are difficult to identify pre-operatively using biopsy
alone. Most lesions meeting criteria for focal ablation were either more aggressive than expected or posed little threat of progression.
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As a consequence of repeated testing for prostate-specific antigen
(PSA), prostate cancer is now the most common male malignancy
in North America and Europe (Jemal et al, 2010). Of the 217 730
men diagnosed with this disease in the United States, approxi-
mately half were classified as low-risk disease (Stamey et al, 2004;
Cooperberg et al, 2007). Recent data from the European
Randomized Screening for Prostate Cancer Trial suggest that
many of these cases pose little threat of disease progression and
that only 1 of every 37–48 men diagnosed by PSA testing may
benefit from aggressive treatment (Roobol et al, 2009). Although
this number-needed-to-treat may reduce as the length of follow-up
increases within this trial, it is likely that overtreatment will still be
prevalent for screen-detected cancers.
The concern surrounding the potential for overtreatment of
localised prostate cancer has led many clinicians to propose
alternative treatment strategies. Some clinicians have advocated
active surveillance, but many patients are hesitant to accept this
approach because of the fear of disease progression (Denberg et al,
2006). Focal prostate ablation has recently emerged as a less
invasive alternative to radical prostatectomy and a more
acceptable approach than active surveillance (Sartor et al, 2008).
The objective of focal ablative intervention is to destroy
cancerous prostate tissue without targeting the entire gland.
High-intensity frequency ultrasound (HIFU), photothermal and
cryotherapy are promising techniques that offer the potential of
lower morbidity when compared with radical surgery, external
beam radiation or brachytherapy. Unfortunately few centres have
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reported long-term outcomes to validate this approach and there
are no reported controlled trials that confirm the efficacy of these
treatments (Onik et al, 2008; Challacombe et al, 2009; Lindner
et al, 2009; Warmuth et al, 2010).
One major concern surrounding the efficacy of focal therapy
stems from the observation that many prostate cancers are not
solitary. Depending upon the patient population selected, how the
tissue was processed and which definitions are used, as many as
50–87% of prostate cancers have multiple sites within the gland
(Meiers et al, 2007). Many of these lesions cannot be detected
pre-operatively by biopsy or imaging.
The present study is based on a cohort of men with screen-
detected prostate cancer, who then underwent radical prostatect-
omy as part of a randomised controlled trial (Donovan et al, 2003).
Our aims were, first, to estimate the proportion of men with
screen-detected prostate cancer for whom focal therapy would be
appropriate. Second, to establish whether measures taken during
the diagnostic process could be used to identify those men for
whom focal therapy would be a suitable treatment of their prostate
cancer. Third, to detail the pathological characteristics of tumours
suitable for focal ablation.
PATIENTS AND METHODS
Patient population
Data used in this analysis were prospectively collected from 525
men who underwent radical prostatectomy within the ProtecT trial
(NCT00632983; HTA 96/20/06; HTA 96/20/99) (inclusion criteria
described in: Donovan et al, 2003; Lane et al, 2010), a large
randomised trial testing the efficacy of prostate cancer treatment
in men detected through population-based PSA testing. Men
recruited into ProtecT study were identified from community
medical practices and aged 50–69 years at initial invitation with no
prostatic symptoms. Men included in this study were those
randomised to or choosing surgery after having been diagnosed
with prostate cancer following a 10 core trans-rectal biopsy
performed because of a single-serum PSA value between 3 and
19.9 ngml1, in whom complete pathological records were
available at the time of this analysis. Men included in the ProtecT
trial were used, as opposed to those from a tertiary center case
series, to avoid biasing the sample towards high-risk tumours. The
study population is described in Table 1.
Pathological analysis
Pathologic assessment of needle biopsy prostate cores and radical
prostatectomy specimens was made by specialist urological
pathologists using standardized protocols and agreed reporting
pro-formas. Prostate biopsy specimens were classified as predict-
ing insignificant disease if they met Epstein’s criteria (PSA density
o0.15 ngml1, Gleason score p6, two cores or less with cancer
and no core containing more than 50% cancer) (Epstein et al,
1994) and predicting low risk if they met the following criteria;
PSA p20 ngml1, Gleason score p6, p50% positive cores,
p20mm cancer and at least 40mm benign tissue (Kattan et al,
2003; Steyerberg et al, 2007). For each tumour, we calculated the
Table 1 Radical prostatectomy features of unifocal and multifocal tumours
Unifocal significant tumours Multifocal tumours
n % n % P-valuea
Multivariable
P-valueb
Total 173 352
Age (years, mean (s.d.)) 61.4 (5.0) 60.7 (4.9) 0.9
Differentiation
Gleason 5 or 6 132 78.6 121 35.2
Gleason 3+4¼ 7 28 16.7 174 50.6
Gleason 4+3¼ 7 4 2.4 38 11.0
Gleason 8–10 4 2.4 11 3.2
Missing 5 2.8 8 2.3 o0.001 0.3
Stage
pT2 149 86.4 212 60.3
pT3 24 13.6 140 39.7 o0.001 0.2
Insignificant cancerc
Insignificant (Epstein) 69 39.9 2 0.6 o0.001 o0.001
Insignificant (Liberal) 118 68.2 39 11.1 o0.001 o0.001
Other pathological features
Vascular invasion 0 0.0 15 4.3 0.001 0.1
HGPIN 150 87.7 331 94.3 0.09 0.3
Seminal Vesicle invasion 1 0.6 29 8.3 o0.001 0.3
Tumour volume (ml, mean (s.d.))
Total 1.18 (1.7) 4.33 (9.7) o0.001 o0.001
Dominant 1.05 (1.7) 3.64 (7.8) o0.001 0.001
Secondary 0.16 (0.4) 0.77 (3.7) 0.08 0.4
Tertiary 0.05 (0.1) 0.15 (0.3) 0.02 0.8
Nomogram score (mean (s.d.))d
Risk of indolent cancer 0.75 (0.2) 0.58 (0.3) o0.001 0.9
Abbreviations: HGPIN¼ high-grade prostatic intraepithelial neoplasia; s.d.¼ standard deviation. aw2-test for all variables except tumour volume, and age (t-test). bBackward elimination
logistic regression using parameters with univariable significance. cHistological definition from the prostatectomy specimen: Epstein’s: o 0.5ml tumour volume, Gleason score o 6,
organ confined; liberal: pT2, Gleason score o6, organ confined, no adverse features. dScore calculated using Kattan–Steyerberg nomogram (Steyerberg et al, 2007).
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pre-operative risk of indolent disease using the Kattan–Steyerberg
Nomogram (Steyerberg et al, 2007) and identified tumours that
satisfied the proposed consensus criteria predicting tumour
unifocality (i.e., PSA p10 ngml1 or PSADp0.15 ngml1 g1,
Gleason sum score p6, cumulative cancer volume p10mm,
p7mm of cancer within one core andp33% of needle cores with
cancer) (Sartor et al, 2008).
Radical prostatectomy specimens were completely embedded,
mapped and the tumour apportioned between five regions:
anterior to the urethra, posterior left, posterior right, posterior
apical and posterior base. Tumours located entirely or mostly (no
more than 20% of volume in an adjacent region) within one
prostate region were defined as solitary tumours. Tumour volume
was calculated using a three-dimensional method (Chen et al,
2003). Multiple tumours were identified as those with discrete
malignancies separated by one low-power field diameter. The
tumour with the most advanced stage, highest grade or highest
volume was defined as the dominant tumour. Insignificant
tumours in the prostatectomy specimens were classified according
to the Epstein’s criteria (p0.5ml tumour volume, Gleason score
p6, organ confined) (Epstein et al, 2005) and more liberal criteria
(any volume, pT2, Gleason score p6, organ confined, no adverse
features (e.g., vascular invasion)) (Sengupta et al, 2008; Lee et al,
2009). Solitary single cancers and multifocal tumours with a
dominant solitary focus and insignificant secondary foci were
defined as those suitable for focal therapy.
Statistical analysis
Measures made before surgery were evaluated for their ability to
identify those suitable for focal therapy using univariable logistic
regression, a multivariable model determined by backward
selection and Harrell’s concordance index (Harrell et al, 1982;
Catto et al, 2009). For regression, we analysed age of the patient,
serum PSA, prostate volume, PSA density, Gleason grade, digital
rectal examination findings and measures of tumour extent in the
biopsy core. Independence between variables was determined
before inclusion (ro0.5) and separate models used for collinear
variables. The predictive power of the final multivariable models
was evaluated using sensitivity, specificity, positive predictive
value, and the area under the receiver operating characteristic
curve. All tests were two-tailed, performed within SPSS statistical
software (Version 18.0, 2010, SPSS Inc., Chicago, IL, USA) and
significance was defined as a P-value o0.05.
RESULTS
We report data from 525 men within the ProtecT trial who
underwent radical prostatectomy with curative intent. At diag-
nosis, the average patient age was 61 years (s.d. 5), the average
serum PSA was 6.1 ngml1 (s.d. 3.6) and the average prostate size
was 34.4ml (TRUS volume, s.d. 15.2). Of the 525 men, 512 (97.5%)
harboured Gleason score 6 or 7 disease, 496 (94.5%) had 10 or
more biopsy cores assessed and 423 (80.6%) were diagnosed
following the first biopsy. Solitary prostate cancers were identified
in the prostatectomy specimens of 100 (19%) men (Table 1,
Figure 1A). Of these, tumour was located in a single region in 66
and in two adjacent regions in 34 men. The remaining 425 men
had multifocal lesions consisting of either a diffuse dominant
tumour (200 men, 47%) or multiple cancers (225 men, 53%). In
these men, the secondary lesions were insignificant in 33% (73 out
of 225) and hence may be suitable for focal treatment (Eggener
et al, 2007). Thus, 33% of men (173 out of 525) had tumours
suitable for focal ablation (i.e., unifocal significant tumours).
Men with unifocal significant tumours had a lower Gleason score
(w2-test, Po0.001), lower stage (Po0.001), fewer cores positive
at biopsy (mean¼ 11% of cores had cancer (95% CI: 6–16%))
vs 33% for multifocal tumours (28–38%), ANOVA Po0.001),
less disease within these cores (mean cumulative length of
unifocal cancer¼ 6mm (95% CI: 3–10mm) vs 20mm for multi-
focal disease (16–25mm, ANOVA Po0.001)) and less vascular
invasion in the prostatectomy specimen than those with multi-
focal disease (w2-test, P¼ 0.06) (Table 1). Of note, multifocal
tumours were found more easily than unifocal ones (84% detected
at first biopsy vs 73% for unifocal cancers, w2-test, P¼ 0.007).
Multivariable analysis revealed that tumour unifocality was most
associated with pathologically defined insignificant disease and
tumour volume (Po0.0001). Focal ablation is not recommended
for tumours with poorly differentiated components or with
capsular invasion (Sartor et al, 2008). In total, 118 out of 173
(68%) of unifocal cancers were Gleason score p6 and pT2. Of
these, 69 out of 118 (58%) and 118 out of 118 (100%) were
pathologically insignificant according to Epstein’s and the liberal
definitions, respectively. Therefore, between 56 out of 123 (47%)
and 9 out of 123 (7%) of unifocal tumours were Gleason 6, pT2 and
pathologically significant, depending upon the definition of
pathological insignificance.
Several pre-operative measures were associated with the
presence of a unifocal cancer (Table 2). Owing to covariate
correlation (r40.5), biopsy features describing tumour extent
(bilateral disease, total and maximal tumour length and percentage
of cores with cancer) and insignificant cancer definitions were
incorporated separately into models. The likelihood of unifocal
disease increased with a high nomogram score (HR 4.3 (95% CI:
1.8–10.5)), in tumours fulfilling the focal treatment criteria (HR
2.4 (1.5–3.8)) and those appearing as low risk on biopsy (HR 2.9
(1.8–4.4)). In contrast, tumour bilaterality on biopsy (HR 0.27
(0.17–0.42)), increasing numbers of involved cores (HR 0.49
(0.04–0.9)) and high Gleason grade (HR 0.6 (0.4–0.9)) reduced the
risk of unifocal disease. When compared with other parameters,
bilateral disease on biopsy was the feature most strongly associated
with multifocal disease.
On the basis of this information available following prostate
biopsy, 130 (25%) of the 525 men were predicted as being suitable
for focal ablation (Table 3, Figure 1B). A review of their surgical
specimens showed that 92 (71%) of these men harboured well-
differentiated tumours. In total, 39% met Epstein’s criteria and
56% met the more liberal criteria for insignificant disease. Overall,
31 (24%) had Gleason grade 4 elements and 14 (11%) had
extracapsular extension. Multifocal disease was present in 106 out
Radical prostatectomy specimens
n =525 Unifocal significant
disease
Insignificant
disease (liberal)
Insignificant
disease
(Epstein’s
definition)
Gleason 4 and pT2
Gleason 4 and pT3 9%
15%
2% Gl.6 pT3
39%
56%
18%
Solitary tumour
n =100
Single
region
n =66
Adjacent
regions
n =34
Multiple
tumours
n =225
Single
tumour
n =200
Insignificant
secondary
lesions n =73
Unifocal lesion or insignificant
disease elsewhere
n =173 (33%)
14% pT3
13% pT2 and Gleason 4
38% Insignificant (Epstein’s criteria)
66% Insignificant (liberal criteria)
Multifocal tumour
n =425
Figure 1 Tumour focality in prostate cancer. (A) Flowchart of tumour
focality within the samples described within this report. (B) The
pathological details of tumours fulfilling the criteria for focal therapy. The
thick black line represents the 2% of tumours that are pT3 and Gleason
3þ 3¼ 6.
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of 130 (82%) of these men. Of these, the second focus was
pathologically insignificant in 61 out of 106 (57%). If these criteria
were used to direct focal ablation within our patients, they would
have correctly identified 18% of men with clinically significant
solitary tumours; but would have also included 56% of men with
pathologically insignificant tumours and 26% of men with poorly
differentiated or locally advanced cancers (Figure 1A).
The criteria used to select men for focal prostate ablation did not
reliably identify solitary lesions (Concordance index (C-in-
dex)¼ 0.50), pathologically significant disease (C-index¼ 0.64–
0.71), tumour stage (C-index¼ 0.65), tumour grade (C-in-
dex¼ 0.68) or tumour volume (C-index¼ 0.75). Men meeting
these criteria were likely to harbour smaller tumours in larger
prostates when compared with the other men in the study cohort
(Table 3). In fact, the criteria developed to identify men for focal
treatment were more likely to select patients on the basis of
prostate volume (C-index¼ 0.76) rather than tumour parameters.
DISCUSSION
Our study demonstrates that focal prostate ablation is an inappro-
priate therapy for the majority of men presenting with PSA-detected
localised prostate cancer. We found that measures available following
prostate biopsy could not reliably identify men with solitary tumours
amenable for focal therapy. Among men who do harbour well-
differentiated solitary lesions, the majority are small lesions that
are probably best managed by active surveillance.
Consensus criteria developed by experts to identify men for
focal prostate ablation mostly relied on prostate weight and
tumour volume and thus did not reliably identify clinically
significant solitary prostate lesions. Of greater concern, these
criteria included as many as one quarter of the men harbouring
Gleason grade 4 disease or with capsular invasion (Figure 1B).
When we evaluated all the measures available following prostate
biopsy, we found that markers of tumour extent could accurately
identify men who should not receive focal prostate ablation, but we
were unable to identify reliably those men with solitary lesions
who would benefit from focal therapy. For example, when more
than 50% of biopsy cores were involved with tumour, we found
that most of these tumours (495%) were multifocal. In contrast,
multifocal disease was present in 75% of men with only 1mm of
cancer in one biopsy core. Our data support the concept of
template-mapping protocols before performing regional ablation,
and suggest the need for formal prospective evaluation of this
method.
Our study may be limited in that it underestimates the proportion
of solitary or insignificant cancers present in contemporary European
or North-American practices. Reports describing these populations,
however, reveal a similar proportion of solitary, multifocal or bilateral
lesions to that we observed in our data (Table 4). Frequent testing
for PSA may find prostate cancers earlier in their natural history,
but the anatomical distribution of these cancers appears to be
comparable to those identified in the United Kingdom.
In summary, our analysis suggests that the majority of men
presenting with prostate cancer following testing for PSA are
inappropriate candidates for focal prostate ablation. Men who
harbour solitary prostate cancers most often have insignificant
disease that might be best managed by active surveillance (van den
Bergh et al, 2009), whereas men harbouring multi-focal prostate
cancers usually have clinically significant disease that requires
more extensive treatment.
Table 2 Pre-operative features of unifocal and multifocal prostate cancers
Unifocal Multifocal HR 95% CI
Mean s.d. Mean s.d.
P-value
Univariable analysisa
P-value
Multivariable analysisb HR Low High
Interval data
Serum PSA at diagnosis (ngml1) 5.5 3.1 6.4 3.8 0.005 0.07
TRUS prostate volume (ml) 36.8 16.2 33.2 14.5 0.014 0.3
PSA density 0.17 0.14 0.22 0.16 0.001 0.08
Total length of tissue (mm) 131.3 35.7 130.7 33.9 0.9
Positive cores (% of total) 11 31.4 33 47.2 o0.001 0.001 0.49 0.04 0.9
Cumulative cancer length (mm) 6 24.5 20 40.4 o0.001 0.09
Maximal tumour length (mm) 3.1 2.7 5.1 5.7 o0.001 0.08
Nomogram prediction 0.75 0.24 0.58 0.29 o0.001 o0.001 4.3 1.8 10.5
Categorical data n % n %
Gleason score
Gleason 5–6 151 87.3 239 67.9
Gleason 7 20 11.5 102 29.2
Gleason 8–10 2 1.2 10 2.9 o0.001 0.009 0.6 0.4 0.9
Number of biopsy sessions
One 126 72.8 297 84.4
Two or more 47 27.2 55 15.6 0.007 0.1
Number of biopsy cores
10 or fewer 131 75.7 297 84.4
More than 10 42 24.3 55 15.6 0.3
Lobes involved 2008 Focal therapy criteria, insignificant cancer
Bilateral 36 20.8 164 46.6 o0.001 o0.001 0.27 0.17 0.42
Yes 68 42.8 62 18.2 o0.001 0.002 2.4 1.5 3.8
Epstein’s criteria 59 37.1 51 15.0 o0.001 0.9 0.9 0.83 0.97
Low risk 134 77.5 171 48.6 o0.001 0.001 2.9 1.8 4.4
Abbreviations: CI¼ confidence interval; HR¼Hazards ratio; PSA¼ prostate-specific antigen; TRUS¼ transrectal ultrasound. aANOVA for continuous and w2-test for categorical
data. bBackward elimination logistic regression.
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Table 3 Pathological features of tumours fulfilling pre-operative criteria for focal ablation
Suitable for focal ablation Unsuitable for focal ablation
n % n % v2-test, P-value
Total 130 370
Age (mean (s.d.)) 61.3 (5.1) 60.6 (4.9)
Differentiation
Gleason 5 or 6 92 70.8 143 38.6
Gleason 3+4¼ 7 30 23.1 166 44.9
Gleason 4+3¼ 7 1 0.8 41 11.1
Gleason 8–10 0 0.0 14 3.8
Missing 7 5.4 6 1.6 o0.001
Stage
pT2 114 87.7 216 58.4
pT3 14 10.8 145 39.2
Missing 2 1.5 9 2.4 o0.001
Insignificant cancera
Insignificant (Epstein) 47 39.2 28 8.2 o0.001
Insignificant (liberal) 73 56.2 70 19.7 o0.001
Other pathological features
Vascular invasion 0 0.0 15 4.1 0.02
HGPIN 121 93.1 338 91.8 0.65
Seminal Vesicle invasion 1 0.8 29 7.9 0.003
Perineural invasion 11 8.5 109 29.8 o0.001
Prostatectomy findings
Single tumour 17 13.1 94 25.4
Multiple tumours 113 86.9 276 74.6 0.004
Unifocal disease 24 18.5 67 18.1
Multifocal cancers 106 81.5 303 81.9 0.93
Tumour volume
Mean (s.d.) 1.51 (3.2)ml 4.04 (9.3)ml o0.001
Prostate volumeb
Mean (s.d.) 42.8 (17.5) ml 31.4 (13.3)ml o0.001
Prostatectomy weight
Mean (s.d.) 56.5 (21.4) g 46.2 (17.2) g o0.001
Abbreviations: HGPIN¼ high-grade prostatic intraepithelial neoplasia; s.d.¼ standard deviation. aHistological definition from the prostatectomy specimen. bDetermined by
transrectal ultrasound (TRUS) measurement. t-test, P-value.
Table 4 Previous reports of prostate cancer size and location
Reference Center Collection Selection N Country
Solitary or
unilateral (%)
Villers et al (1992) Single Retro None 234 United States 50
Miller and Cygan (1994) Single Retro None 151 United States 44
Djavan et al (1999) Single Retro None 308 Austria 33
Wise et al (2002) Single Retro None 486 United States 17
Noguchi et al (2003) Single Retro T1c disease 222 United States 24
Ng et al (2004) Single Retro None 364 United States 15
Eichelberger and Cheng (2004) Single Retro None 312 United States 15
Horninger et al (2004) Single Retro PSA o4.0 ngml1 80 Austria 35
Cheng et al (2005) Single Retro Small volume (o0.5ml) 62 United States 31
Torlakovic et al (2005) Single Retro None 46 Croatia 35
Muezzinoglu et al (2006) Multi Retro None 947 United States, Turkey and Japan 27
Scales et al (2007) Multi Retro Low riska 261 United States 35
Mouraviev et al (2007) Single Retro None 1184 United States 19
Tareen et al (2009) Single Retro None 1467 United States 21
Polascik et al (2009) Single Retro Low/intermediate riskb 538 United States 23
Ward et al (2009) Single Retro Unilateral disease on biopsy 180 United States 17
This series Multi Prospective None 525 United Kingdom 33
Mean 28
Abbreviation: PSA¼ prostate-specific antigen. aT1c or T2a, PSAp10 ngml1, Gleason p6 and less than three positive cores. bpT2c, PSAp10 and Gleason p7.
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